Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02655-18. doi: 10.1128/AAC.02655-18. Print 2019 Jun.


Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of β-lactamase Resistance Genes and Lineage Background in the United States.

Mendes RE, Jones RN, Woosley LN, Cattoir V, Castanheira M.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S69-S78. doi: 10.1093/ofid/ofz004. eCollection 2019 Mar.


Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying bla KPC-2 Reveals a Heterogenous Population and Reversible Genotype.

Castanheira M, Arends SJR, Davis AP, Woosley LN, Bhalodi AA, MacVane SH.

mSphere. 2018 Sep 26;3(5). pii: e00408-18. doi: 10.1128/mSphere.00408-18.


Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Int J Antimicrob Agents. 2018 Aug;52(2):287-292. doi: 10.1016/j.ijantimicag.2018.04.001. Epub 2018 Apr 11.


Retrospective molecular analysis of DIM-1 metallo-β-lactamase discovered in Pseudomonas stutzeri from India in 2000.

Deshpande LM, Jones RN, Woosley LN, Castanheira M.

Antimicrob Agents Chemother. 2014;58(1):596-8. doi: 10.1128/AAC.01541-13. Epub 2013 Oct 21.


Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.

Castanheira M, Woosley LN, Messer SA, Diekema DJ, Jones RN, Pfaller MA.

Antimicrob Agents Chemother. 2014;58(1):577-80. doi: 10.1128/AAC.01674-13. Epub 2013 Oct 14.


Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme.

Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M.

Mycopathologia. 2012 Oct;174(4):259-71. doi: 10.1007/s11046-012-9551-x. Epub 2012 May 13.


Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010.

Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2012 Mar;56(3):1639-42. doi: 10.1128/AAC.06067-11. Epub 2011 Dec 19.


Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09).

Castanheira M, Mendes RE, Woosley LN, Jones RN.

J Antimicrob Chemother. 2011 Jun;66(6):1409-11. doi: 10.1093/jac/dkr081. Epub 2011 Mar 18. No abstract available.


Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.

Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA.

Antimicrob Agents Chemother. 2010 Jun;54(6):2655-9. doi: 10.1128/AAC.01711-09. Epub 2010 Apr 5.


CEM-101 activity against Gram-positive organisms.

Woosley LN, Castanheira M, Jones RN.

Antimicrob Agents Chemother. 2010 May;54(5):2182-7. doi: 10.1128/AAC.01662-09. Epub 2010 Feb 22.


Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus.

Jones RN, Castanheira M, Rhomberg PR, Woosley LN, Pfaller MA.

J Clin Microbiol. 2010 Mar;48(3):972-6. doi: 10.1128/JCM.01829-09. Epub 2010 Jan 6.

Supplemental Content

Loading ...
Support Center